uniQure (NASDAQ:QURE) Stock Crosses Above 200-Day Moving Average – Here’s Why

uniQure (NASDAQ:QURE)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $9.38 and traded as high as $14.24. uniQure shares last traded at $14.18, with a volume of 595,499 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Leerink Partners raised their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. Stifel Nicolaus raised their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Cantor Fitzgerald raised their price target on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. Finally, Mizuho raised their price objective on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

uniQure Trading Up 7.0 %

The firm has a market capitalization of $691.18 million, a price-to-earnings ratio of -2.86 and a beta of 0.38. The business’s 50-day simple moving average is $15.41 and its two-hundred day simple moving average is $9.38. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its holdings in shares of uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 969 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in shares of uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after buying an additional 1,371 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after buying an additional 1,503 shares during the last quarter. Northern Trust Corp raised its position in uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after purchasing an additional 1,923 shares during the last quarter. Finally, Twin Tree Management LP acquired a new position in uniQure in the 4th quarter valued at $77,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.